Six new lawsuits and three clinical trials, tracked on September 1, 2026, could reshape how GLP-1 drugs are priced, marketed, and used. Five lawsuits target Novo Nordisk and one targets Eli Lilly, all over pricing and marketing practices for drugs like Ozempic, Wegovy, and Zepbound. None of the filings are public yet, but a win for any plaintiff could change what patients pay. Two trials are also testing new uses for these drugs, in teens and in diabetics with dementia.
This case is one of several pending against Novo Nordisk, and it specifically challenges how the company prices and sells its GLP-1 drugs. If the plaintiff succeeds, the ruling could set a precedent that affects how Novo Nordisk structures its pricing going forward, and possibly how it markets drugs like Ozempic and Wegovy to patients and providers. The filing itself is not yet public, so the specific allegations and requested remedies are not known. Patients who rely on these medications may want to watch this case closely, since a change in pricing practice at Novo Nordisk could influence costs across the broader GLP-1 market.
A separate case, filed against Eli Lilly, raises similar questions but focuses on that company's marketing and pricing of its own GLP-1 products, which include Zepbound and Mounjaro. As with the Novo Nordisk suits, the underlying claims have not been made public, so it is not yet clear whether the complaint centers on advertising language, price transparency, or something else entirely. What is clear is that Eli Lilly, like Novo Nordisk, now faces legal scrutiny over how it communicates cost and value to consumers. Anyone weighing the price of a Lilly GLP-1 product may want to keep an eye on how this case develops, since the outcome could shape future disclosures.
This third case against Novo Nordisk differs from the others in one respect: it claims the company misrepresented not just the price of its GLP-1 drugs, but their availability as well. That distinction matters, because a shortage claim raises different legal and regulatory questions than a pricing claim alone, touching on whether patients were given accurate information about whether a drug like Ozempic or Wegovy could actually be filled at a given pharmacy. The case remains active, though specific details have not yet been released. If the claims are substantiated, the ruling could affect how drug makers communicate supply information to patients and prescribers in the future.
Turning to the research side, a phase 3 trial beginning in 2026 will examine whether teens and children can safely restart Wegovy just two weeks after undergoing weight-loss surgery. This question matters because sleeve gastrectomy and GLP-1 medications are increasingly used together in younger patients, yet there has been limited data on how soon a drug like semaglutide can be reintroduced after surgery without added risk. The trial is currently recruiting, which means results are still some time away. Families considering both surgical and drug-based treatment for adolescent obesity may want to note this study, since its findings could eventually inform clinical guidance for combining the two approaches.
A second trial, also recruiting, is testing whether mazdutide, a GLP-1-related drug, can slow memory loss in people with type 2 diabetes who show early signs of dementia. This research points to a potential use for GLP-1 drugs beyond diabetes and weight management, extending into cognitive protection for a population that already faces elevated health risks. The study is in phase 3, meaning it has already passed earlier stages of testing. Because dementia in people with diabetes is a serious and growing concern, the outcome of this trial could matter well beyond the diabetes and obesity communities that have driven most GLP-1 demand so far.
None of the six lawsuits described here have public filings yet, so it is too early to know how any of them will affect the price or marketing of Ozempic, Wegovy, or Zepbound. I would suggest that readers who take these medications keep watching for updates as the filings become public, since the claims themselves will clarify what changes, if any, might follow. In the meantime, the two clinical trials are worth following for different reasons: one could inform care for teens combining surgery and medication, and the other could expand the role of GLP-1 drugs in protecting cognitive health for people with diabetes. Staying informed on both fronts, the courts and the research, will give patients a clearer picture of where this treatment class is heading.
Key details
A lawsuit against Novo Nordisk could change how GLP-1 drugs are priced and sold.
A separate lawsuit accuses Eli Lilly of deceptive GLP-1 marketing and pricing.
Another case claims Novo Nordisk misrepresented GLP-1 drug prices and availability.
A 2026 trial will test if teens can safely restart Wegovy after weight-loss surgery.
A trial is testing if a GLP-1 drug can slow memory loss in diabetics with dementia.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-09-01
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.